This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, K. C.
Right arrow Articles by Critchley, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, K. C.
Right arrow Articles by Critchley, I. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Antibiotics

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 2230-2235, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.00049-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel{triangledown}

Kimberley Clawson Stone,1 Ron Dagan,2 Adriano Arguedas,3 Eugene Leibovitz,2 Elaine Wang,4 Roger M. Echols,4 Nebojsa Janjic,1 and Ian A. Critchley1*

Replidyne, Inc., Louisville, Colorado 80027,1 The Pediatric Infectious Disease Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,2 Instituto de Atención Pediátrica and Universidad de Ciencias Médicas, San José, Costa Rica,3 Replidyne, Inc., Milford, Connecticut 064604

Received 13 January 2007/ Returned for modification 27 February 2007/ Accepted 14 March 2007

Faropenem was tested against 1,188 middle ear fluid pathogens from children in Israel and Costa Rica. Against Streptococcus pneumoniae and Haemophilus influenzae, faropenem was the most active ß-lactam, with activity that was similar to or greater than of the other oral antimicrobial classes studied. Faropenem was also active against Moraxella catarrhalis and Streptococcus pyogenes.

* Corresponding author. Mailing address: Replidyne Inc., 1450 Infinite Drive, Louisville, CO 80027. Phone: (303) 996-5531. Fax: (303) 996-5599. E-mail: icritchley{at}replidyne.com

{triangledown} Published ahead of print on 26 March 2007.

Antimicrobial Agents and Chemotherapy, June 2007, p. 2230-2235, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.00049-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kosowska-Shick, K., McGhee, P., Appelbaum, P. C. (2009). Binding of Faropenem and Other {beta}-Lactam Agents to Penicillin-Binding Proteins of Pneumococci with Various {beta}-Lactam Susceptibilities. Antimicrob. Agents Chemother. 53: 2176-2180 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Clark, C., Credito, K., Dewasse, B., Beachel, L., Ednie, L., Appelbaum, P. C. (2008). In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother. 52: 748-752 [Abstract] [Full Text]  
  • Critchley, I. A., Brown, S. D., Traczewski, M. M., Tillotson, G. S., Janjic, N. (2007). National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study. Antimicrob. Agents Chemother. 51: 4382-4389 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»